Clinical Drug Investigation

, Volume 25, Issue 8, pp 507–515

Long-Term Effects of Rivastigmine Treatment on the Need for Psychotropic Medications in Nursing Home Patients with Alzheimer’s Disease

Results of a 52-Week Open-Label Study
  • Keith Edwards
  • Barbara Koumaras
  • Michael Chen
  • Ibrahim Gunay
  • Dario Mirski
  • Rivastigmine Nursing Home Study Team
Original Research Article

Abstract

Background and objective: Neuropsychiatric symptoms and behavioural disturbances occur in most patients with Alzheimer’s disease (AD), are a source of stress for caregivers, and are the primary cause of patient institutionalisation. These symptoms often are treated with psychotropic medications. However, adverse drug interactions, adverse effects and nursing home regulations make reducing the use of psychotropic medications in elderly AD patients an important goal of therapy. Fifty-two-week data including data from a 26-week prospective open-label, multicentre study and its 26-week open-label extension were analysed.

Patients and methods: 173 patients with moderate to severe AD residing in nursing homes were treated with rivastigmine 1.5–6mg twice daily. In the study, psychotropic drug use and behavioural symptoms were measured at baseline and at 52 weeks.

Results: Results showed that 40% of patients who were receiving psychotropic medications at baseline had discontinued use or reduced their dose of psychotropic medications at week 52. Furthermore, significant improvements were observed from baseline in 10 of the 12 behavioural domains of the Nursing Home version of the Neuropsychiatric Inventory, including delusions (mean change from baseline −2.0; p = 0.002), hallucinations (mean change −3.1; p < 0.001), anxiety (mean change −1.1; p = 0.014), and euphoria (mean change −3.2; p = 0.006).

Conclusion: These data suggest favourable tolerability, behavioural and pharmacoeconomic outcomes in nursing home residents with AD who are treated with rivastigmine.

References

  1. 1.
    Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60(8): 1119–22PubMedCrossRefGoogle Scholar
  2. 2.
    Mega MS, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer’s disease. Neurology 1996; 46(1): 130–5PubMedCrossRefGoogle Scholar
  3. 3.
    Chen JC, Borson S, Scanlan JM. Stage-specific prevalence of behavioral symptoms in Alzheimer’s disease in a multi-ethnic community sample. Am J Geriatr Psychiatry 2000; 8(2): 123–33PubMedGoogle Scholar
  4. 4.
    Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County study on memory in aging. Am J Psychiatry 2000; 157(5): 708–14PubMedCrossRefGoogle Scholar
  5. 5.
    Levy ML, Cummings JL, Kahn-Rose R. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer’s disease. Gerontology 1999; 45Suppl. 1: 15–22PubMedCrossRefGoogle Scholar
  6. 6.
    Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer’s disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc 1998; 46(2): 210–5PubMedGoogle Scholar
  7. 7.
    Gurvich T, Cunningham JA. Appropriate use of psychotropic drugs in nursing homes. Am Fam Physician 2000; 61(5): 1437–46PubMedGoogle Scholar
  8. 8.
    Risperdal [package insert]. Titusville (NJ): Janssen Pharmaceutica Products LP, 2005Google Scholar
  9. 9.
    Zyprexa [package insert]. Indianapolis (IN): Eli Lilly and Company, 2005Google Scholar
  10. 10.
    Farlow MR, Hake A, Messina J, et al. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 2001; 58(3): 417–22PubMedCrossRefGoogle Scholar
  11. 11.
    Burns A, Spiegel R, Quaig P. Benefits of rivastigmine in patients with severe Alzheimer’s disease (AD). 41st Annual Meeting of the American College of Neuropsychopharmacology; 2002 Dec 8–12; San Juan, Puerto RicoGoogle Scholar
  12. 12.
    McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356(9247): 2031–6PubMedCrossRefGoogle Scholar
  13. 13.
    Giladi N, Shabtai H, Gurevich T, et al. Rivastigmine (Exelon) for dementia in patients with Parkinson’s disease. Acta Neurol Scand 2003; 108(5): 368–73PubMedCrossRefGoogle Scholar
  14. 14.
    Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351(24): 2509–18PubMedCrossRefGoogle Scholar
  15. 15.
    Moretti R, Torre P, Antonello RM, et al. Rivastigmine in vascular dementia. Expert Opin Pharmacother 2004; 5(6): 1399–410PubMedCrossRefGoogle Scholar
  16. 16.
    Grossberg GT, Stahelin HB, Messina JC, et al. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry 2000; 15(3): 242–7PubMedCrossRefGoogle Scholar
  17. 17.
    McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34(7): 939–44PubMedCrossRefGoogle Scholar
  18. 18.
    Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44(12): 2308–14PubMedCrossRefGoogle Scholar
  19. 19.
    Cummings JL, Anand R, Koumaras B, et al. Rivastigmine provides behavioral benefits to Alzheimer’s disease patients residing in a nursing home: findings from a 26-week trial [abstract no. S79.002]. Neurology 2000; 54: A468Google Scholar
  20. 20.
    Aupperle PM, Koumaras B, Chen M, et al. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer’s disease: results of a 52-week open-label study. Curr Med Res Opin 2004; 20(10): 1605–12PubMedCrossRefGoogle Scholar
  21. 21.
    Motsinger CD, Perron GA, Lacy TJ. Use of atypical antipsychotic drugs in patients with dementia. Am Fam Physician 2003; 67(11): 2335–40PubMedGoogle Scholar
  22. 22.
    Cadieux RJ. Drug interactions in the elderly: how multiple drug use increases risk exponentially. Postgrad Med 1989; 86(8): 179–86PubMedGoogle Scholar
  23. 23.
    Katona CL. Psychotropics and drug interactions in the elderly patient. Int J Geriatr Psychiatry 2001; 16Suppl. 1: S86–90PubMedCrossRefGoogle Scholar
  24. 24.
    Polinsky RJ. Clinical pharmacology of rivastigmine: a newgeneration acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Clin Ther 1998; 20(4): 634–47PubMedCrossRefGoogle Scholar
  25. 25.
    Bentue-Ferrer D, Tribut O, Polard E, et al. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs 2003; 17(13): 947–63PubMedCrossRefGoogle Scholar
  26. 26.
    Desai AK. Use of psychopharmacologic agents in the elderly. Clin Geriatr Med 2003; 19(4): 697–719PubMedCrossRefGoogle Scholar
  27. 27.
    Frels C, Williams P, Narayanan S, et al. Iatrogenic causes of falls in hospitalised elderly patients: a case-control study. Postgrad Med J 2002; 78(922): 487–9PubMedCrossRefGoogle Scholar
  28. 28.
    FDA public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. Food and Drug Administration. Available from URL: www.fda.gov/cder/drfxg/advisory/antipsychotics.htmDate [Accessed 2005 May 23]
  29. 29.
    Darvesh S, Grantham DL, Hopkins DA. Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. J Comp Neurol 1998; 393(3): 374–90PubMedCrossRefGoogle Scholar
  30. 30.
    Rosier M, Retz W, Retz-Junginger P, et al. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer’s disease. Behav Neurol 1998; 11(4): 211–6Google Scholar
  31. 31.
    Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998; 1: 55–65Google Scholar
  32. 32.
    Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54(12): 2269–76PubMedCrossRefGoogle Scholar
  33. 33.
    Cummings JL, Schneider L, Tariot PN, et al. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer’s disease. Am J Psychiatry 2004; 161(3): 532–8PubMedCrossRefGoogle Scholar
  34. 34.
    Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc 2001; 49(12): 1590–9PubMedCrossRefGoogle Scholar
  35. 35.
    Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998; 158(9): 1021–31PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Keith Edwards
    • 1
  • Barbara Koumaras
    • 2
  • Michael Chen
    • 2
  • Ibrahim Gunay
    • 2
  • Dario Mirski
    • 2
  • Rivastigmine Nursing Home Study Team
  1. 1.Alzheimers Diagnostic CenterBenningtonUSA
  2. 2.Novartis Pharmaceuticals Corp.East HanoverNew JerseyUSA

Personalised recommendations